Drugs / IBI-20089
last change Nov 2014 re-read 2 minutes ago

IBI-20089

Developed for
age-related macular degeneration · choroidal neovascularization
Investigated by
ICON Bioscience Inc · University of Illinois at Chicago

Trials 1 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01175395 Sep 2010 → Jan 2013 age-related macular degeneration, choroidal neovascularization University of Illinois at Chicago Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as IBI-20089 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01175395
Known as IBI-20089 (Triamcinolone Acetonide) IBI-20089 (Triamcinolone Acetonide)NCT01175395
Route Intravitreal “a single intravitreal injection of IBI-20089” PMID 25376617 Nov 2014